Galderma S.A. is a Swiss pharmaceutical company of specializing in dermatological treatments and skin care products. Formerly a subsidiary of L'Oreal and then of Nestlé, it has been held by a consortium of private institutional investors since 2019.
Galderma was formed in 1981 as a joint venture between Nestlé and L'Oréal. Since 2019, it belongs to an investment fund. The company, headed by President & CEO Flemming Ornskow (ex-Shire), has 33 affiliates in 100 countries with a worldwide network of distributors and employs more than 5,000 people. The parent company is based in Lausanne, Switzerland.
Galderma provides a range of products used to treat acne, rosacea, psoriasis and other steroid-responsive dermatoses (SRD), onychomycosis (fungal nail infections), pigmentary disorders, skin cancer and skin senescence. Galderma's products sell in more than 70 countries.
In 2019, Nestlé sold Galderma for $10.2 billion to a consortium comprising the EQT VIII fund, Luxinva (a wholly owned subsidiary of Abu Dhabi Investment Authority), PSP Investments and other institutional investors. Since then, it has been the largest dermatology company in the world.
According to en.wikipedia
